Superficial thrombophlebitis and risk for recurrent venous thromboembolism  by Schönauer, Verena et al.
Superficial thrombophlebitis and risk for recurrent
venous thromboembolism
Verena Scho¨nauer, MD,a Paul A. Kyrle, MD,a Ansgar Weltermann, MD,a Erich Minar, MD,b
Christine Bialonczyk, MD,c Mirko Hirschl, MD,d Peter Quehenberger, MD,e Barbara Schneider, PhD,f
Hugo Partsch, MD,c and Sabine Eichinger, MD,a Vienna, Austria
Objective: Superficial thrombophlebitis (ST) is a frequent and potentially serious disease if complicated with venous
thromboembolism (VTE). Data on risk factors and incidence rates for ST are scarce. It is also unknown whether ST is a
risk factor for recurrence of VTE.
Methods: After discontinuation of secondary thromboprophylaxis for a first spontaneous VTE, we prospectively observed
615 patients on average for 30 26 months. Patients with natural coagulation inhibitor deficiency, lupus anticoagulant,
or cancer, who were pregnant, or were receiving long-term antithrombotic therapy were excluded. The study outcomes
were occurrence of symptomatic ST or objectively documented recurrent symptomatic VTE.
Results: ST developed in 45 patients (7.3%) with a first VTE. High factor VIII concentration emerged as an independent
risk factor for ST (relative risk [RR], 2.0; 95% confidence interval [CI], 1.0-5.2), compared with lower levels after
adjustment for age and sex; factor V Leiden and prothrombin G20210A concentration; hyperhomocysteinemia; high
body mass index; and duration of oral anticoagulation therapy. VTE recurred in 12 (27%) of 45 patients with ST and in
67 (12%) of 570 patients without ST. In patients with VTE, subsequent ST emerged as an independent risk factor for
recurrent VTE. Patients with ST had twofold higher RR (2.1; 95% CI, 1.0-4.2) for recurrence than did patients without
ST after adjustment for putative confounding variables.
Conclusion: Patients with a first spontaneous VTE and subsequent ST are at increased risk for recurrent VTE. High factor
VIII concentration is an independent risk factor for ST. (J Vasc Surg 2003;37:834-8.)
Superficial thrombophlebitis (ST) of the lower limbs is
common, affecting 3% to 11% of the general population.1
ST is regarded as a benign disease that usually has a self-
limited clinical course.2 Its complications, however, can be
serious or even fatal; an association with deep vein throm-
bosis (DVT)3-6 and pulmonary embolism (PE)7 has been
reported.
In patients with varicose veins, ST frequently is trig-
gered by minor trauma, but data on risk factors for ST in
these patients or in patients without varices are otherwise
limited.2 A higher rate of ST has been noted among pa-
tients with natural coagulation inhibitor deficiency8-11 and
among carriers of the factor V Leiden mutation.11,12 Data
on the significance of prothrombin G20210A as a risk
factor for ST are controversial.11,12 Incidence of ST seems
to be higher in overweight persons, and high body mass
index (BMI) has been described as an independent risk
factor.12
Risk for recurrence in patients with venous thrombo-
embolism (VTE) has been extensively studied, and ranges
from 5% to 40% during the first years after discontinuation
of secondary thromboprophylaxis, depending on the pres-
ence of acquired or congenital risk factors.13,14 The risk for
subsequent ST in patients with a history of VTE, however,
has not been investigated. Most important, it is unknown
whether patients with a history of VTE and subsequent ST
are at higher risk for recurrent VTE than those without ST.
We prospectively observed patients with a first sponta-
neous VTE to evaluate the incidence of and risk factors for
subsequent ST. We then compared risk for recurrent VTE
after a first VTE in patients with and without subsequent
ST.
MATERIALS AND METHODS
Patient population. All patients enrolled in the Aus-
trian Study on Recurrent Venous Thromboembolism (AU-
REC) were eligible for the present analysis. AUREC is an
ongoing prospective study involving four thrombosis cen-
ters in Vienna, Austria. Patients (older than 18 years) with
a first objectively documented VTE treated with oral anti-
coagulant therapy for at least 3 months were included.
Patients with VTE secondary to trauma, surgery, or preg-
nancy, or who had natural coagulation inhibitor deficiency,
lupus anticoagulant, or cancer, or who needed long-term
antithrombotic therapy for reasons other than VTE were
excluded.
All patients had initially been given unfractionated or
low molecular weight heparin in therapeutic doses. Patients
entered the study at the time of discontinuation of oral
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anticoagulant therapy. Patients were seen at 3-month in-
tervals during the first year and then every 6 months.
Patients were instructed to report any symptoms of ST or
VTE.
The study was approved by the ethics committee of the
University of Vienna, and written informed consent was
provided by all patients.
Diagnosis of venous thromboembolism. The diag-
nosis of DVT was made on the basis of positive findings at
venography or color duplex scanning. The diagnosis was
established at venography when one of three criteria was
fulfilled: constant filling defect seen on two views; abrupt
discontinuation of the contrast medium-filled vessel at a
constant level of the vein; or absence of filling in the entire
deep vein system, without compression, with or without
venous flow through collateral veins. The diagnosis was
established at duplex scanning if one of two criteria was
met: visualization of an intraluminal thrombus in a deep
vein, or incomplete compressibility or absence of compress-
ibility.
Diagnostic criteria for PE were positive findings at
ventilation-perfusion lung scanning according to the crite-
ria of the Prospective Investigation of Pulmonary Embo-
lism Diagnosis15 or at spiral computed tomography (CT) if
one or more low-attenuation areas were noted that partly
or completely filled the lumen of an opacified vessel.
Study end points. End points of the study were symp-
tomatic ST or recurrence of symptomatic VTE. Symptom-
atic ST was diagnosed on the basis of clinical findings such
as painful induration and redness of a superficial vein in the
lower extremity. Only patients with a high clinical proba-
bility of recurrent DVT underwent duplex scanning (n 9)
or venography (n  1). Recurrent DVT was confirmed at
venography or duplex scanning, in patients with proximal
DVT of the contralateral leg only; and at ventilation-
perfusion lung scanning or spiral CT in patients with symp-
tomatic PE. Findings had to meet the same criteria as for
diagnosis of venous thromboembolism. In patients under-
going venography, DVT was considered to have recurred if
the patient had a thrombus in the leg other than the one
with the previous thromboembolic event; a thrombus in
another deep vein in the same leg as affected by the previous
event; or a thrombus in the same venous system as affected
by the previous event, with proximal extension of the
thrombus, if the upper limit of the original thrombus had
been visible, or with a constant filling defect surrounded by
contrast medium if the original thrombus had not been
visible.
Laboratory analysis. After the patient had fasted
overnight, venous blood was collected in a 1:10 dilution of
0.11M trisodium citrate. A portion of the blood was cen-
trifuged for 20 minutes at 2000g. Another portion of the
blood was immediately centrifuged at 1600g for 20 min-
utes at 4° C for measurement of homocysteine; the plasma
was then snap-frozen and stored at 80° C. Genomic
DNA was isolated from leukocytes with standard methods.
Determination of antithrombin, protein C, protein S,
factor VIII, and homocysteine concentrations was per-
formed as reported.16 Screening for factor V Leiden and
prothrombin G20210A was carried out as described.17,18
The presence of lupus anticoagulant was assessed according
to the criteria of the International Society on Thrombosis
and Haemostasis.19 Laboratory technicians were blinded to
patient characteristics at all times.
Statistical analysis. Time to occurrence of ST or
recurrent VTE (uncensored data) and follow-up time in
patients without ST or without recurrent VTE (censored
data) were analyzed with survival time methods.20 The
probability of ST or recurrent VTE was estimated with the
Kaplan-Meier method.21 To test for homogeneity between
strata, we used the log-rank test and the generalized Wil-
coxon test. Relative risk for recurrence was estimated with a
Cox regression model with ST as a time-dependent covari-
able. Data were adjusted for age and sex; factor V Leiden
and prothrombin G20210A concentration; hyperhomo-
cysteinemia (dichotomized at the 95th percentile of nor-
mal) and high factor VIII concentration (dichotomized at a
plasma level of 234 IU/dL); duration of oral anticoagula-
tion therapy; and high BMI (25 kg/m2), calculated by
dividing weight in kilograms by the square of height in
meters.
Categorial data were checked for homogeneity with
contingency table analyses (2 test). Simple descriptive
statistics were computed to provide clear presentation of
data. For numerical operations a SAS software package was
used. Values are given as mean SD or median and range.
RESULTS
Risk for ST in patients with VTE. The study pop-
ulation consisted of 615 patients with a first spontaneous
VTE (367 DVT, 248 PE with or without DVT). After
discontinuation of oral anticoagulation therapy, patients
were followed up on average for 30 (26) months. One
hundred eighty-two patients were excluded because they
had cancer (n  11), required antithrombotic therapy for
reasons other than VTE (n  99), became pregnant (n 
17), or were lost to follow-up (n 51). One patient died of
gastric cancer, 1 died of septicemia, and 2 patients died of
heart failure. Data for these patients were censored at
exclusion or death.
ST subsequently developed in 45 of 615 patients
(7.3%). In all patients, ST was treated with compression
therapy and ambulation. In addition, 22 patients received
low molecular weight heparin for 10 days, and 8 patients
were given nonsteroidal antiinflammatory drugs. The me-
dian time between discontinuation of secondary thrombo-
prophylaxis for VTE and subsequent ST was 8 months
(range, 1-68 months).
With the Kaplan-Meier method, cumulative probability
of ST in patients with a first spontaneous VTE was 7.3% (CI,
5.2%-10.1%), 10.6% (CI, 7.4%-13.7%), and 12.8% (CI, 8.3%-
17.2%) at 2, 4, and 6 years, respectively, after discontinuation
of secondary thromboprophylaxis (Figure). For comparison,
cumulative probability of recurrent VTE was 10.7% (CI,
7.9%-13.5%), 17.9% (CI, 13.9%-22.0%), and 23.7% (CI,
18.0%-29.4%) at 2, 4, and 6 years, respectively.
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Characteristics of patients with and without ST are shown
in Table I. Patients with ST were significantly older than
patients without ST (56  12 years vs 48  17 years; P 
.003) and were followed up longer (41 28 months vs 29
26 months; P .004). The proportion of patients with high
BMI (25 kg/m2) was significantly larger among patients
with ST compared with those without ST (82% vs 63%; P 
.007). Incidence of ST was comparable between patients with
proximal or distal DVT (8.1% and 6.2%; P .8).
High levels of factor VIII confer substantial risk for
both first and recurrent VTE. We therefore investigated
the role of factor VIII with regard to risk for ST. Com-
pared with patients without ST, a significantly larger
proportion of patients with ST had high factor VIII
levels (24% vs 10%; P  .004). Compared with patients
with low factor VIII levels, patients with high factor VIII
levels had a fourfold relative risk for ST (RR, 4.0; CI,
2.0-8.6), which remained significant after adjustment for
age and sex; factor V Leiden and prothrombin G20210A
concentration; hyperhomocysteinemia; high BMI; and
duration of oral anticoagulation therapy (RR, 2.0; CI,
1.0-5.2).
Recurrence of venous thromboembolism. Of 615
patients, 79 (13%) had recurrent VTE, including 12 (27%;
5 DVT, 7 PE, respectively) of 45 patients with ST and 67
(12%; 47 DVT, 20 PE, respectively) of 570 patients with-
out ST. Median time between ST and recurrent VTE was
17  14 months (range 2 to 39) months.
The primary purpose of this study was to evaluate the
influence of ST on risk for subsequent VTE, which implies






Pn % n %
Sex (male) 256 45 22 50 NS
Age at VTE (y) 48  17 56  12 .003
VTE at inclusion in study
DVT 340 60 27 60 NS
PE 230 40 18 40 NS
Duration of anticoagulation (mo) 8  11 13  29 NS
Factor V Leiden 183 33 16 36 NS
Prothrombin G20210A 43 8 5 11 NS
Hyperhomocysteinemia 143 27 10 23 NS
High factor VIII (234 IU/dL) 52 10 11 24 .004
High Body mass index (25 kg/m2) 342 63 36 82 .007
Follow-up (mo) 29  26 41  28 .004
ST ipsilateral to first DVT — 32 71 —
VTE, Venous thromboembolism; ST, superficial thrombophlebitis; DVT, deep venous thrombosis; PE, pulmonary embolism; NS, not significant.
*Plus or minus values are mean  SD.
Estimated risk for ST in 615 patients with a first spontaneous VTE (Kaplan-Meier method).
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a time-dependent association between ST and recurrent
VTE. Hence, for calculation of RR for recurrent VTE, ST
was taken as a time-dependent variable in the regression
model. In this model, crude RR for recurrent VTE among
patients with VTE and subsequent ST was 3.3 (CI, 1.7-
6.3). ST remained a risk factor for recurrent VTE after
adjustment for age and sex; factor V Leiden, prothrombin
G20210A, and high factor VIII concentration; hyperho-
mocysteinemia; high BMI; and duration of anticoagulation
therapy (RR, 2.1; CI, 1.0-4.2) (Table II).
DISCUSSION
In a large cohort of patients with a first spontaneous
VTE, we prospectively evaluated the incidence of and risk
factors for ST, and the association between ST and risk for
subsequently recurrent VTE. Two years after discontinua-
tion of secondary thromboprophylaxis, the probability for
ST in patients with VTE was 7%. At this time, the proba-
bility for ST and recurrent VTE (11%) are comparable, but
risk for ST becomes progressively lower thereafter. At 6
years, risk for recurrent VTE is almost twice as high as risk
for ST (24% vs 13%).
A high factor VIII concentration is a potent risk factor
for a first VTE as well as recurrent VTE.16,22-24 High factor
VIII concentration is also an independent risk factor for ST
(adjusted RR, 2.0, compared with patients with lower
levels). Although this association has been established in
patients with a history of VTE, it can be assumed that a high
factor VIII concentration is also a risk factor for ST in
persons without prior VTE. Factor V Leiden did not
emerge as a risk factor for ST in our patients. This finding is
in contrast to two studies in which factor V Leiden con-
ferred a twofold to sixfold higher risk for ST.11,12 In both
studies, however, the study cohort consisted of patients
without a history of VTE. In confirmation of the Swiss
study, the proportion of patients with excess body weight
was also significantly greater among patients with ST com-
pared with those without ST.12
The principal finding of our study was that patients
with a first spontaneous VTE and subsequent ST were at
threefold increased risk for recurrent VTE compared with
patients without ST. When confounding variables were
considered in the logistic regression model, RR was some-
what reduced, mainly because of high factor VIII concen-
tration. However, ST still remained an independent risk
factor for recurrent VTE in patients with thrombosis.
The diagnosis of symptomatic ST was established on
the basis of characteristic clinical signs and symptoms. Only
patients with a high clinical probability of recurrent VTE
underwent duplex scanning or venography. ST is fre-
quently associated with DVT and PE.3-7,25 However, we
consider it unlikely that the higher risk for recurrence in
patients with ST could have resulted from recurrent VTE
that was overlooked at the time of ST, for the following
reasons. Concomitant DVT was ruled out at duplex scan-
ning or venography in one fourth of patients. Most impor-
tant, all patients were closely followed up until resolution of
symptoms of ST. Within 2 months after the diagnosis, no
patients had VTE and no patients with ST had symptoms of
PE.
Patients with a first spontaneous VTE and subsequent
ST are at increased risk for recurrent VTE. High factor VIII
concentration, which is a risk factor for recurrent VTE, is
also an independent risk factor for ST. The results of an
ongoing interventional trial will show whether prolonging
secondary thromboprophylaxis is beneficial in patients with
high factor VIII concentration and a first VTE.
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